Innovation Type: Medication


Innovation Origin: Accelerated Access Collaborative (AAC)

For treating highly active relapsing-remitting multiple sclerosis in adults

A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment and monitoring burden. See further detail at the the Merck website.

This innovation is being supported by the Accelerated Access Collaborative - for more details about the AAC, see the AHSN's dedicated web page, or the AAC's official home page.

For more information, please visit:

< Back to Innovation Finder

Contact us

If you'd like to discuss this Innovation, have an idea or a new Innovation, please get in touch.